NCT03505710 - DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

181

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

May 3, 2021

Study Completion Date

April 17, 2024

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Trastuzumab deruxtecan

Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.

Trial Locations (21)

8035

Hospital Universitari Vall d'Hebron, Barcelona

10065

Memorial Sloan Kettering Cancer Center, New York

12915

Hôpital Nord - CHU Marseille, Marseille

28041

Hospital 12 de Octubre, Madrid

31059

CHU Larrey, Toulouse

Hôpital Larrey, CHU-Toulouse, Toulouse

33612

Moffitt Cancer Center, Tampa

48109

University of Michigan, Ann Arbor

48201

Karmanos Cancer Institute, Detroit

63110

Washington University School of Medicine at St. Louis, St Louis

69008

Centre Leon Berard, Lyon

80045

University of Colorado Hospital, Aurora

92093

University of California San Diego (UCSD), La Jolla

94805

Institut Gustave Roussy, Villejuif

98109

University of Washington, Seattle

02215

Dana-Farber Cancer Institute, Boston

277-8577

National Cancer Center Hospital East, Kashiwa

589-8511

Kindai University Hospital, Ōsaka-sayama

411-8777

Shizuoka Cancer Center, Nakatogari

104-0045

National Cancer Center Hospital, Chuo Ku

1066CX

Netherlands Cancer Institute, Amsterdam